摘要
目的 :观察2型糖尿病大鼠血糖、血清胰岛素浓度和胰岛素受体底物-2(insulin receptor substrate 2,IRS-2)的蛋白表达变化及祛胰抵方对其变化的影响。方法 :以小剂量链脲佐菌素(30 mg/kg)腹腔注射合并高脂饮食诱导2型糖尿病大鼠模型,给予不同剂量祛胰抵方治疗12周。分别测定其血糖、血清胰岛素浓度、肝脏组织的IRS-2蛋白表达。结果 :造模后2型糖尿病大鼠的血糖、血清胰岛素升高,肝脏组织的IRS-2蛋白表达下降;祛胰抵方能降低模型大鼠的血糖和血清胰岛素,并能显著升高肝脏组织IRS-2的蛋白表达。结论 :祛胰抵方治疗2型糖尿病可能与其提高肝脏组织IRS-2的蛋白表达从而改善胰岛素信号传导有关。
Objective ： To investigate blood glucose, insulin and the protein expression of insulin receptor substrate-2 （ IRS-2 ） of type 2 diabetes mellitus （ T2DM ） rats and effects of Quyidi Prescription on these indexes. Methods ： Model rats of T2DM were induced by intraperitoneal injectin of low dose streptozotocin（ 30 mg/kg ） and fed on high fat-diet. Model rats were treated with different doses Quyidi Prescription for twelve weeks. After treatment, all rats were killed and following indexes were measured： blood glucose, insulin, expression of IRS- 2 protein in liver. Resuhs ： After building model, the blood glucose, insulin of T2DM rats were increased, and expression of IRS-2 protein in liver was decreased in T2DM rats. Quyidi Prescription can reduce the blood glucose and insulin and increase the expression of IHS-2 protein in liver of T2DM rats. Conclusion ： The mechanism of Quyidi Prescription treating T2DM may be partly by raising IRS-2 protein expression in liver to improve insulin resistance.
出处
《辽宁中医药大学学报》
CAS
2014年第3期7-9,共3页
Journal of Liaoning University of Traditional Chinese Medicine
基金
黑龙江省自然科学基金项目(D201072)
关键词
2型糖尿病
祛胰抵方
胰岛素受体底物-2
type 2 diabetes mellitus（ T2DM ）
Quyidi Prescription
insulin receptor substrate-2（ IRS-2）
